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Life-threatening pericarditis and pleuritis caused by influenza B 
and successfully treated during COVID-19 pandemic
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i skutecznie wyleczone podczas pandemii COVID-19
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Abstract
In 2020, World Health Organization declared severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection 
[coronavirus disease 2019 (COVID-19)] a pandemic. Nowadays, Influenza A (InfA) and COVID-19 seem to be a major 
threat. We report the rare case of life-threatening exudative pericarditis (without myocardial involvement) and pleuritis 
in an adult patient without inherited diseases, caused by Influenza B (not by COVID-19/InfA) and successfully treated 
(including: oseltamivir, pericardiocentesis 700 mL, pleurocentesis 1100 mL) in the COVID-19 pandemic. Although 
Influenza B is a rare cause of pericarditis, we should consider it as a possible reason of a potentially lethal disease.
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Introduction
Influenza causes 300,000 deaths per year in the world 
[1]. Although the respiratory system is commonly affected, 
cardiac involvement also occurs (direct virus impact on 
heart or preexisting cardiovascular disease exacerbation) 
[2]. In 2020, World Health Organization (WHO) declared 
SARS-CoV-2 (severe acute respiratory syndrome corona-
virus 2) infection (COVID-19, coronavirus disease 2019) 
a pandemic. Influenza A (InfA) and COVID-19 seem to 
be a major threat. Influenza B (InfB) is considered less 
severe than InfA, typically causing mild upper respiratory 
symptoms [3].
Authors report the rare case of life-threatening pe-
ricarditis (without myocardial involvement) and pleu-
ritis, caused by InfB and successfully treated during 
a COVID-19 pandemic.
Case report
A 74-year-old patient with I/II/III degree atrioventricular 
block, after pacemaker implantation (19.02.2020) and 
right ventricular (RV) electrode replacement (dysfunction, 
21.02.2020), was admitted to hospital (19.03.2020) 
because of confirmed (Doppler-ultrasound) left brachial, 
axillary vein thrombosis and fever (up to 38°C) for 7 days.
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revealed pericardial effusion at RV 5 mm, no systolic RV and 
left ventricular (LV) dysfunction. Transesophageal echocar-
diography (TOE) showed no vegetations. Pharmacotherapy 
was provided: ointment (heparin, phenyl butasone), rivarox-
aban 2 × 15 mg, ketoprofen, and empirical treatment with 
vancomycin. Inflammatory markers decreased, but hectic 
fever (to 38.5°C) of unclear etiology persisted.
Urine cultures and tumor markers [CA125, CA19.9, 
carcinoembryonic antigen (CEA), CA15.3, prostatic specific 
antigen (PSA)] were negative. Abdominal computed tomo-
graphy (CT) revealed fluid in pelvis 17 mm; chest CT fluid 
in pericardium 23 mm, in left pleura 43 mm (Figure 1). 
TTE showed fluid at RV 5 mm, LV posterior wall (LVPW) 
11 mm, right atrium (RA) 11 mm, without wall perforation. 
Initially, the patient’s state was good, without dyspnea, 
stenocardia, cough; 36.8°C, the pacemaker pocket healed 
properly. Upper left extremity was swollen, warm.
COVID-19 was excluded. “Cassette” screening test and 
reverse transcriptase polymerase chain reaction (RT-PCR) 
(nasopharyngeal swab, days: 1, 14) were negative.
Methicillin resistant Staphlylococcus aureus (MRSA), 
Klebsiella pneumoniae carbapenemase (KPC) (swabs), 
tuberculosis (QuantiFERON) were excluded. Inflammatory 
markers elevated: C-reactive protein (CRP) 205 mg/L, D-di-
mers 0.69 mg/L FEU, white blood cells WBC 12,000/µL, 
with negative procalcitonin.
Cardiac device-related infectious endocarditis (CDRIE) 
was suspected. Transthoracic echocardiography (TTE) 
Figure 1A. Chest computed tomography (CT): fluid in pericardium 23 mm; B. Chest CT: fluid in left pleura 43 mm
A B
Figure 2. Transthoracic echocardiography prior to pericardiocentesis: pericardial effusion at right ventricle 15 mm, posterior wall of left 
ventricle (LV) 25 mm, lateral wall of LV 27 mm, right atrium 26 mm: A. Long axis view; B. Four chamber apical view
A B
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Proteinogram confirmed acute inflammation. Hypothyroi-
dism was excluded.
Blood cultures were negative. TOE was repeated (days 
1, 7): no vegetations, pericardial effusion 22 mm, with-
out tamponade, 5 mm fibrin layer. There was no data for 
CDRIE. Initial diagnosis was reactive/inflammatory pericar-
dial and pleural effusion. Colchicine, ibuprofen, levofloxa-
cin were administered.
Control Doppler-ultrasound (after week) showed resid-
ual 1.5–2.0 mm thick wall thrombus in left axillary veins. 
Rivaroxaban dose was reduced (20 mg/day).
After 10 days of treatment: clinical worsening, still fever, 
increasing CRP (238 [mg/l]), WBC (14,500/µL), D-dimers 
(7.89 mg/l FEU)) were observed. Paroxysmal atrial fibrilla-
tion/atrial tachycardia appeared (after fluid evacuation: spon-
taneous sinus rhythm recurrence). TTE showed pericardial 
effusion at RV 15 mm, LVPW 25 mm, RA 26 mm (Figure 2).
Nasopharyngeal swab samples were negative for InfA, 
positive for InfB. Oseltamivir 2 × 75 mg and furosemide 
were provided (control swab after 5 days: negative).
Due to pericardial and pleural (82 mm) effusion, 
pericardiocentesis (700 mL, serosanguinous fluid) and 
pleurocentesis (1100 mL, serous fluid) were performed 
(02.04.2020), with clinical improvement. Pericardial fluid 
examination revealed exudate, negative cultures (aerobic, 
anaerobic, fungal, TBC). Pleural fluid analysis showed exu-
date, negative cultures (aerobic, anaerobic, TBC).
Anti-cardiolipin antibodies (ACA: IgM, IgG), anti-nucle-
ar nRNP, anti-neutrophil (cANCA, pANCA), antinuclear and 
cytoplasmic ANA (HEP-2), Legionella, Bartonella, Tulare-
mia antibodies were negative. Mycoplasma pneumoniae 
and Chlamydia pneumoniae IgM antibodies were nega-
tive, IgG were positive (previous infections). Prednisone 
(30–100–0 mg) was provided.
Finally, clinical improvement, no fever recurrence and 
CRP reduction (15) were achieved. Control TTEs revealed 
stable pericardial effusion at LVPW 18 mm, RA 13 mm. The 
patient was discharged with diagnosis of exudative peri-
carditis and pleuritis in the course of InfB.
Follow-up: continuous decrease in pericardial effusion.
Discussion
Cardiac involvement is more common and better described 
with InfA than InfB [3].
Few cases of myopericarditis were described in the co-
urse of: COVID-19 (pericardiocentesis 540 mL) [4], and InfB 
(fatal tamponade, pericardiocentesis 240 mL) [3].
Only few cases of pericarditis (without myocardial invol-
vement) were reported, but in “high risk” patients with co-
-morbidities, during: InfA (first case: hypertension, nicoti-
nism; pericardiocentesis 250 mL, ibuprofen, colchicum, 
oseltamivir [2]; second case: alcohol, cocaine; pericardio-
centesis, antibiotic, oseltamivir, nonsteroidal anti-inflam-
matory drugs (NSAIDs), colchicum [5]) and InfB (21 triso-
my, ASD; ibuprofen, colchicum, oseltamivir, steroids, furo-
semide) [1].
We report a rare case of life-threatening exudative pe-
ricarditis (without myocardial involvement) and pleuritis in 
an adult patient without inherited diseases caused by InfB 
(not by COVID-19/InfA) and successfully treated in a CO-
VID-19 pandemic. However, InfB is a rare cause of pericar-
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Streszczenie
W 2020 roku Światowa Organizacja Zdrowia ogłosiła panedmię spowodowaną SARS-CoV-2 (severe acute respiratory 
syndrome coronavirus 2) (choroba koronawirusowa 2-19 [COVID-19]). Infekcje grypą A (InfA) i COVID-19 są obecnie trak-
towane jako większe zagrożenie niż infekcja grypą B. Zaprezentowano rzadki przypadek zagrażających życiu wysiękowe-
go zapalenia osierdzia (bez zajęcia miokardium) i opłucnej u dorosłego pacjenta (bez chorób dziedzicznych), wywołanych 
przez grypę B (nie przez COVID-19/InfA) oraz skutecznie wyleczonych (w tym: oseltamiwir, perikardiocenteza 700 ml, 
pleurocenteza 1100 ml) w czasie pandemii COVID-19. Mimo że grypa B jest rzadką przyczyną zapalenia osierdzia, to 
należy ją traktować jako możliwą przyczynę potencjalnie śmiertelnej choroby.
Słowa kluczowe: grypa B, zapalenie osierdzia, zapalenie opłucnej, pandemia COVID-19, SARS-CoV-2
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